Prevalence of antibodies to respiratory syncytial virus in various populations in Israel
Related Experiment Video
Updated: Aug 20, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 11, 2013
Insights
This study found that antibody acquisition to respiratory syncytial virus (RSV) occurs later in life for this population compared to Western countries. Higher prevalence was observed in older children and adults, with significant levels in hospitalized infants.
Area of Science:
- Immunology
- Virology
- Pediatrics
Background:
- Respiratory syncytial virus (RSV) is a common respiratory pathogen.
- Understanding RSV antibody prevalence is crucial for public health strategies.
- Previous studies indicate earlier RSV antibody acquisition in Western populations.
Purpose of the Study:
- To determine the prevalence of antibodies to RSV across different age groups in the local population.
- To compare RSV antibody acquisition timing with that reported in Western countries.
Main Methods:
- A preliminary seroprevalence study was conducted.
- Antibody levels to RSV were measured in various age cohorts, including infants, children, and adults.
- Prevalence data was analyzed based on age and health status (healthy vs. hospitalized).
Main Results:
- RSV antibody prevalence was 27% in healthy infants (6-12 months), increasing to 37% (1-2 years) and 54% (2-4 years).
- Prevalence reached 78% in healthy adults (>20 years).
- Hospitalized infants (6-12 months) showed significant antibody levels in 59% of cases.
Conclusions:
- RSV antibody acquisition in this population appears to occur later in life compared to Western nations.
- The findings highlight a potential difference in epidemiological patterns of RSV infection.
- Further research is warranted to confirm these observations and explore contributing factors.
Abstract:
A preliminary study on the prevalence of antibodies to respiratory syncytial virus (RSV) in individuals of various age-groups was carried out. In healthy infants aged 6 to 12 months, the prevalence was 27%. It increased to 37 and 54% in children aged 1 to 2 and 2 to 4 years, respectively. The prevalence reached 78% in healthy individuals who were more than 20 years old, including pregnant women. Significant levels of specific antibodies were detected in 59% of children aged 6 to 12 months who were hospitalized with respiratory tract illnesses. It appears that acquisition of antibodies to RSV in our population occurs relatively later in life than in other Western countries.
Related Concept Videos
01:51Vaccinations
01:29Respiratory Syncytial Virus Disease